GlassScriptPhysician profile
Mikhail Lezhak
NPI 1184807166
$3,302.11
in general payments reported to CMS, 2019-2025
31 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $311 · 2022: $603 · 2023: $609 · 2024: $525 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,225 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,225.06 |
| Education | $162.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $424.08 | 2021-2025 | Provenge |
| Astellas Pharma US INC | $413.39 | 2021-2025 | Myrbetriq, Xtandi, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $248.10 | 2022-2025 | |
| Janssen Biotech, INC. | $228.17 | 2021-2024 | Erleada, Akeega |
| Novartis Pharmaceuticals Corporation | $219.38 | 2022-2025 | |
| Pfizer INC. | $203.68 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $197.14 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Endo Pharmaceuticals INC. | $164.49 | 2023-2024 | Xiaflex, Aveed |
| Myriad Genetic Laboratories, INC. | $117.27 | 2023-2025 | Prolaris |
| Ferring Pharmaceuticals INC. | $116.52 | 2024-2025 | Adstiladrin |
| Abbvie INC. | $114.80 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.14 | 2021 | |
| Seagen INC. | $84.99 | 2025 | |
| Endo USA, INC. | $71.71 | 2024-2025 | Aveed, Xiaflex |
| Dentsply Ih INC. | $58.26 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $55.90 | 2023-2025 | Jelmyto |
| Telix Pharmaceuticals | $54.46 | 2025 | Illuccix |
| Medtronic, INC. | $49.61 | 2025 | Interstim |
| Tolmar, INC. | $48.35 | 2023-2025 | Jatenzo, Eligard |
| Tempus Ai, INC | $45.41 | 2025 | Xt Cdx |
| Tolmar Pharmaceuticals, INC. | $40.77 | 2022 | |
| Blue Earth Diagnostics | $35.40 | 2024 | |
| Boston Scientific Corporation | $35.39 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $35.32 | 2024-2025 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $26.79 | 2022 | |
| Verity Pharmaceuticals INC. | $26.56 | 2022-2023 | Trelstar |
| Foundation Medicine, INC. | $25.72 | 2023 | |
| Celgene Corporation | $24.84 | 2022 | |
| Smith+Nephew, INC. | $19.58 | 2023 | Stravix Pl |
| Immunitybio, INC. | $16.05 | 2024 | |
| Sun Pharmaceutical Industries INC. | $11.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Lezhak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.